Table 6.
Extra-list drugs with evidence from phase III clinical trial.
| Generic name | Indication | Date of marketing | Whether in the formal review list | The main reasons for negative reimbursement decision |
|---|---|---|---|---|
| Olaparib tablets | Metastatic castration-resistant prostate cancer | Jun. 16th, 2021 | Yes (2021) | Already in NRDL, applying for another indication, need to reduce price again |
| Osimertinib mesylate tablets | Non-small-cell lung cancer | Apr. 7th, 2021 | No | Already in NRDL, applying for another indication, need to reduce price again |
| Lenvatinib mesilate capsules | Thyroid carcinoma | Nov. 4th, 2020 | No | Already in NRDL, applying for another indication, need to reduce price again |
| Pertuzumab injection | Unresectable or metastatic HER2-low breast cancer | Dec. 6th, 2019 | Yes (2021) | Competing products with the same indication in NRDL,such as Trastuzumab Emtansine for Injection; Already in NRDL, applying for another indication, need to reduce price again |
| Atezolizumab injection | Hepatocellular carcinoma | Oct. 28th, 2020 | No | Competing products, Donafenib Tosilate Tablets and Lenvatinib Mesilate Capsules with the same indication in NRDL, |
| Enzalutamide soft capsules | Non-Metastatic Castration-Resistant Prostate Cancer | Nov. 2nd, 2020 | No | Competing products, Apalutamide Tablets and Darolutamide Tablets with the same indication in NRDL; |
| Gilteritinib fumarate tablets | Acute myeloid leukemia | Jan. 30th, 2021 | No | Competing product, Azacitidine for Injection, with the same indication in NRDL |
| Pralatrexate injection | Peripheral T cell lymphoma | Aug. 26th, 2020 | Yes (2020, 2021) | Competing product, Trastuzumab Emtansine for Injection, with the same indication in NRDL |
| Venetoclax tablets | Acute myeloid leukemia | Dec. 2nd, 2020 | Yes (2021) | Competing product, Azacitidine for Injection, with the same indication in NRDL, |
| Trastuzumab emtansine for injection | HER2-positive early breast cancer | Jan. 21st, 2020 | Yes (2020) | Competing product, Azacitidine for Injection, with the same indication in NRDL |
| Palbociclib capsules | Receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer | Jul. 31st, 2018 | Yes (2020, 2021) | Competing product, Abemaciclib Tablets, with the same indication in NRDL |
| Trifluridine and tipiracil hydrochloride tablets | Metastatic colorectal cancer | Aug. 29th, 2019 | Yes (2020, 2021) | Competing products, Fruquintinib Capsules and Regorafenib Tablets, with the same indication in NRDL |
| Nivolumab injection | Gastric cancer and adenocarcinoma of esophagogastric junction | Mar. 12th, 2020 | Yes (2020, 2021) | Competing product, Regorafenib Tablets, with the same indication in NRDL |
| Pembrolizumab injection | Squamous cell carcinoma of the head and neck | Dec. 8th, 2020 | Yes (2021) | Competing product, Regorafenib Tablets, with the same indication in NRDL; Negotiations failed due to high price |
| Nivolumab injection | Malignant pleural mesothelioma | Jun. 8th, 2021 | Yes (2021) | Negotiations failed due to high price |
| Pembrolizumab injection | Non-small-cell lung cancera | Mar. 28th, 2019 | Yes (2021) | Negotiations failed due to high price |
| Pembrolizumab injection | Non-small-cell lung cancerb | Sept. 29th, 2019 | Yes (2021) | Negotiations failed due to high price |
| Pembrolizumab injection | Non-small-cell lung cancerc | Nov. 22nd, 2019 | Yes (2021) | Negotiations failed due to high price |
| Pembrolizumab injection | Esophageal squamous cell carcinoma | Jun. 17th, 2020 | Yes (2021) | Negotiations failed due to high price |
| Ipilimumab injection | Malignant pleural mesothelioma | Jun. 8th, 2021 | Yes (2021) | Negotiations failed due to high price |
| Atezolizumab injection | Small cell lung cancer | Feb. 13th, 2020 | Yes (2020) | Reasons not disclosed |
| Durvalumab injection | Non-small-cell lung cancer | Dec. 6th, 2019 | Yes (2020,2021) | Reasons not disclosed |
| Lenalidomide capsules | Multiple myeloma | Dec. 20th, 2017 | No | Reasons not disclosed |
| Lenalidomide capsules | Lymphoma | Nov. 17th, 2020 | No | Reasons not disclosed |
| Nivolumab injection | Non-small cell lung cancer | Jun. 15th, 2018 | Yes (2020,2021) | Reasons not disclosed |
| Nivolumab injection | Squamous cell carcinoma of neck | Sept. 29th, 2019 | Yes (2020,2021) | Reasons not disclosed |
| Plerixafor injection | Lymphoma | Nov. 30th, 2018 | Yes (2020) | Reasons not disclosed |
| Plerixafor injection | Multiple myeloma | Aug. 26th, 2020 | Yes (2020) | Reasons not disclosed |
| Brentuximab vedotin for injection | Lymphoma | Apr. 13th, 2021 | Yes (2020,2021) | Reasons not disclosed |
| Radium chloride [223Ra] | Prostatic cancer | Aug.26th, 2020 | No | Reasons not disclosed |
| Blinatumomab for injection | Leukemia | Dec. 2nd, 2020 | Yes (2021) | Reasons not disclosed |
a Pembrolizumab in combination with pemetrexed and platinum chemotherapy, is indicated for first-line treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
b Pembrolizumab is indicated as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an NMPA-approved test, with no EGFR or ALK genomic tumor aberrations.
c Pembrolizumab in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with metastatic squamous NSCLC.